Zealand Pharma — Oktober 2024
-
Roche upbeat on obesity as acquisitions continue pipeline refresh https://firstwordpharma.com/story/5899925
-
Zealand Pharma/Deutsche: Indleder dækning med anbefalingen "hold"
Zealand Pharma får anbefalingen "hold" og et kursmål på 815 kr. hos Deutsche Bank, der netop har indledt dækning af det danske biotekselskab. Det fremgår af Bloomberg News. -
Snart tilbage til kursen i februar….spændende hvornår det stopper
-
Danske selskaber sidder på næste fedmeguldmine
En ny type af danskudviklede lægemidler vil kunne vende op og ned på det boomende marked for fedmemedicin. https://finans.dk/erhverv/ECE17500708/danske-selskaber-sidder-paa-den-naeste-fedmeguldmine/?utm_campaign=FINANS Briefing&utm_content=2024-10-07&utm_medium=email&utm_source=finans -
Godmorgen
-
OVERBLIK: Disse selskaber er shortet på det danske aktiemarked https://proinvestor.com/investornyt/1224060/overblik-disse-selskaber-er-shortet-pa-det-danske-aktiemarked
-
dejligt og tiltrængt
-
Zealands partner går skridtet videre med to fase 3-studier i fedtlever https://proinvestor.com/investornyt/1224080/zealands-partner-gar-skridtet-videre-med-to-fase-3-studier-i-fedtlever
-
Zealand Pharma provides U.S. regulatory update on dasiglucagon in congenital hyperinsulinism
-
U.S. Food and Drug Administration (FDA) issues Complete Response Letter (CRL) for dasiglucagon in CHI for up to three weeks of dosing due to the timing of a third-party manufacturing facility reinspection
The reinspection of the facility was completed in August/September 2024 for which a new inspection classification is pending
Zealand remains committed to working with the FDA and the third-party manufacturer to bring dasiglucagon to patients in the U.S. as soon as possible -
Zealand Pharma får endnu en udsættelse hos FDA: Partner-fabrik volder fortsat problemer https://proinvestor.com/investornyt/1224602/zealand-pharma-far-endnu-en-udsaettelse-hos-fda-partner-fabrik-volder-fortsat-problemer
-
FDA-melding til Zealand behøver ikke være stor udfordring, mener Nordnet https://proinvestor.com/investornyt/1224632/fda-melding-til-zealand-behover-ikke-vaere-stor-udfordring-mener-nordnet
-
Måske ikke den største sten i skoen, men det du nyhederne omkring den amerikanske kongres, Novo/Wegovy-afvisningen, absolut gøre - tænker umiddelbart, at alle fedme aktier får det væsentligt sværere fremadrettet end forventet?!
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind